Alvotech Ordinary Shares
ALVOAlvotech is a global biopharmaceutical company specializing in the development and manufacturing of high-quality biosimilar medicines. Focused on creating affordable alternatives to existing biologic treatments, Alvotech aims to enhance patient access to vital therapies across various therapeutic areas.
Company News
Alvotech secured a $75 million term loan facility maturing December 31, 2027, led by GoldenTree Asset Management. This follows a recent $165 million equity raise, further strengthening the company's cash position and liquidity.
Alvotech secured a $75 million term loan facility maturing December 31, 2027, led by GoldenTree Asset Management. This follows a recent $165 million equity raise, further strengthening the company's cash position and liquidity.
Alvotech successfully closed a public offering raising $165 million in aggregate, with underwriters fully exercising their option to purchase additional shares. The offering included a concurrent private placement where Celtic Lux Holdings purchased 10.133 million shares at $3.75 per share on June 16, 2026.
Alvotech closed a public offering raising $165 million in aggregate proceeds, with underwriters fully exercising their option to purchase additional shares. The offering included a concurrent private placement where Celtic Lux Holdings acquired 10,133,333 shares at $3.75 per share.
Alvotech (NASDAQ: ALVO) announced a $152 million share offering, comprising an $85 million public offering in the US at $3.75 per share and a $67 million private placement to institutional investors in the EEA. The company plans to use proceeds for biosimilar drug development, working capital, and operational expenses. BofA Securities, Jefferies,...
